CMS-0053-F adopts the first HIPAA standards for electronic health care claims attachment transactions. The final rule is effective May 26, 2026, and compliance is required by May 26, 2028. It covers the exchange of supporting information for a claim or equivalent encounter, including a health plan's request to a provider and a provider's transmission to the plan. Those exchanges can travel through a clearinghouse and involve clinical documents that must remain associated with the correct claim.
Quick answer. CMS-0053-F does not require a penetration test or set a testing frequency. A payer or clearinghouse commissioning an assessment before its May 26, 2028 compliance date should scope the deployed X12 277 request and X12 275 response paths, the C-CDA attachment, claim and member binding, partner authorization, transformation and delivery, and an electronic signature when the workflow uses one. Stingrai's web and API penetration testing can test the application and API boundaries in that exchange with synthetic records and a retestable evidence trail; other components need to be listed and quoted separately.
This guide is for a US payer security leader, claims operations owner, EDI lead, clearinghouse product owner or procurement team that needs a concrete statement of work. It translates the rule's transaction boundary into buyer-selected security tests. The security tests, example fixtures and proposed deliverables below are recommendations for an assessment, not obligations that CMS added to the rule. The source of each regulatory statement is the operative HHS final rule, with the CMS fact sheet and CMS FAQ used for context.
Start with the transaction the rule actually covers
45 CFR 162.2001 defines a health care claims attachments transaction as either attachment information sent by a health care provider to a health plan in support of a health care claim or equivalent encounter transaction, or a health plan's request to a provider for that information. It is a deliberately bounded definition. The object under test is not every document that a payer stores, and it is not every electronic health record interface. It is the implemented claims attachment exchange, plus the systems that decide whether the request, attachment and claim belong together.
The final rule's 45 CFR 162.2002 adopts the HL7 CDA Release 2 Attachment Implementation Guide for the exchange and specified C-CDA clinical note implementation guides for provider-to-plan attachment information. It adopts X12N 275, Version 6020, implementation specification 006020X314 for provider-to-plan additional information to support a claim or encounter, and X12N 277, Version 6020, implementation specification 006020X313 for a plan's request for more claim information. The 275 is the administrative envelope for attachment information; it is not itself the clinical document. HHS makes that distinction in the final rule preamble.
The rule also adopts an HL7 digital signature implementation guide where a provider uses an electronic signature in the claims attachment transmission. That condition matters for a testing brief. It does not say every attachment needs a new signature. HHS explains that a plan determines when signatures are needed and that the new transaction-time signature standard does not apply to signatures on documents created before transmission. A test should first establish whether the implemented transaction signs an attachment, which actor signs, how the signature is associated with its document and which verifier checks it. The test should not assume that a scanned, previously signed report must be re-signed under this rule.
The CMS FAQ says the rule applies to HIPAA covered entities that conduct the relevant transactions electronically, including providers, health plans and clearinghouses, and limits compliance to transactions they conduct electronically. A buyer should therefore identify its exact role, products and trading-partner flow before asking a vendor to quote. A claims platform may be the payer's property while a clearinghouse operates the gateway, an EDI translator and the partner onboarding portal. Those are different permission boundaries with different owners.
Rule element | What the buyer should identify | Security decision to verify |
|---|---|---|
Plan request, X12N 277 | Which plan, claim, provider and route produced the request | Only the intended provider or authorized delegate receives it, and its claim reference resolves to the intended claim |
Provider attachment, X12N 275 | Which provider or vendor created and sent the response | Only an authorized sender can submit it for the referenced claim; the plan receives the right attachment |
C-CDA attachment information | Which source document, transformation and storage path are used | Document identity and content remain bound to the intended member and claim through conversion, relay and retrieval |
Electronic signature, when used | Who signs, where and when; which service verifies | Signature identity, document integrity and delegation are checked for that transaction |
Clearinghouse relay | Which tenant, partner route, queue and acknowledgment are used | A message cannot cross plan or provider tenant boundaries because of a routing, retry or support action |
The right edge of this table is an assessment design, not a list of CMS-mandated tests. Its value is practical: the vendor can price a defined set of paths and identities, and the buyer can decide whether the returned evidence proves the boundaries it cares about.
Keep CMS-0053-F separate from CMS-0057-F
The CMS-0053-F final fact sheet says the final rule focuses exclusively on claims attachments. HHS did not finalize the proposed prior authorization attachment standards in it. That decision is easy to miss because the proposal discussed both use cases and because a payer may use the same clinical document store for claims and prior authorization.
CMS-0057-F addresses a different set of affected-payer interoperability and prior authorization APIs, generally with API requirements beginning in 2027. Its security questions concern FHIR API access, provider attribution, member permission and prior authorization workflow rights. Our CMS-0057-F API scope guide covers those interfaces. A payer implementing both rules may use shared identity services or data stores, but the contracting brief should give each exchange its own test cases and acceptance criteria.
The distinction also prevents a misleading bid. A vendor promising a generic FHIR API test has not necessarily priced an X12 277 request, X12 275 response, C-CDA transformation or clearinghouse route. Conversely, testing the attachment exchange does not establish the security of the payer's Provider Access or Prior Authorization API. Put shared components in the inventory once, then specify which business rules need distinct verification. The FHIR API penetration testing guide supplies protocol context when a shared FHIR service is truly in scope.
Map the exchange before requesting a proposal
The most useful kickoff artifact is a one-page data-flow map. It should show the entry point, identity asserted at each hop, attachment source, translation point, queue or gateway, final claim association, document store and the user-facing or API retrieval path. The map must include both solicited and, if supported, unsolicited attachments. HHS says in the preamble that the claims X12N 275 may be used for both. A plan that accepts only one should state that limitation.
Figure 1: A buyer-designed assurance map for claims attachment exchange. The transaction directions and standards come from HHS, CMS-0053-F final rule, 45 CFR 162.2001-2002; the test decisions and evidence are editorial recommendations.
Ask the payer and clearinghouse to mark which box owns each decision. A clearinghouse may authenticate trading partners and route EDI, while the payer decides whether a document belongs to a claim and who can view it. The buyer needs written permission for each environment and target, including a hosted onboarding portal and any vendor API. "End to end" should mean named systems and owners, not an assumed right to probe every partner.
Identify every transformation. For example, the provider may select a document in an EHR, an adapter may package it as C-CDA content, an EDI service may place it in a 275, a clearinghouse may validate and relay it, and the payer may index it into a claim record. The tester should know where an identifier can be regenerated or mapped. A correct authorization decision at the first portal does not prove that the document was filed under the right claim after translation.
The inventory should also list exception paths: a malformed message is quarantined, a missing document is resubmitted, a clearinghouse retries, an operator corrects a route, a plan requests more information, or a provider sends an attachment before a request. These paths are often where a valid identity becomes detached from a message. Test them only in an approved nonproduction or controlled environment, using synthetic claims and documents.
Define the identities and records needed for meaningful tests
A vendor cannot validate cross-tenant boundaries with one provider login and one claim. Give the tester a small, deliberately varied fixture set. It can contain two synthetic provider organizations, two synthetic plans if the platform is multi-tenant, two clearinghouse trading-partner accounts where available, distinct members, and multiple claims with similar but nonidentical identifiers. Include one authorized attachment per claim and at least one attachment that should be rejected or held because it belongs elsewhere. All names and clinical content should be invented for the test. No live patient information is needed to prove whether an ownership check works.
Use both positive and negative outcomes. A positive fixture shows that a valid plan request reaches the designated provider and that the authorized 275 attachment is associated with the right claim. A negative fixture asks whether a different provider, plan tenant, member or claim can see or accept that same document. A response that says only "access denied" may be insufficient if the wrong tenant still received an acknowledgment, document preview, metadata or queue entry. The tester should inspect the expected result at every visible hop.
Write the expected decisions before testing. Who may send an unsolicited attachment? Can a delegated billing service act for a provider? Which identifier is authoritative if the 275 envelope and a clinical document disagree? What does the plan do when a 277 request is canceled or a claim is adjusted? When can a provider view an earlier attachment? These questions are product and trading-partner policy questions. The tester verifies the approved policy rather than inventing one during execution.
Test the boundaries that can change the outcome
1. Request identity and provider routing
Start with the plan-originated 277 request. The test should confirm that the issuer is the expected plan or authorized processor, the claim and provider references resolve correctly, and the request reaches only the intended trading partner. Compare a legitimate request with a request carrying a claim from another tenant, a provider identity that no longer has the relationship, or an ambiguous partner route. Expected behavior may be rejection, quarantine or a controlled exception workflow. The buyer should specify it.
The same checks belong in the provider's view of the request. A portal user may have access to several practices or facilities. The application should select the proper organizational context before displaying a requested document type or claim metadata. The tester should examine navigation, search, notifications, downloads and API access under each role. A hidden button is not an authorization decision if the underlying request remains retrievable to the wrong organization.
2. Attachment submission and claim association
For the provider-to-plan 275, verify that the sender has authority for the provider and claim being named, that the attachment type and document identifier survive packaging, and that the final plan record points to the intended member and claim. A claimed match should be confirmed at the payer's ingestion endpoint and retrieval screen, not just at the sending gateway. If the plan permits unsolicited attachments, define a separate case that checks how the attachment is matched and what happens when the claim has not yet arrived.
This is a business-logic test, so the most important fixtures are near misses. Use two synthetic claims for the same member, two members with deliberately similar identifiers, an adjusted claim, a duplicate submission and a document with a mismatched internal patient reference. The tester should observe whether the system rejects, quarantines, flags or intentionally accepts each case according to policy. The goal is to verify authorization and association, not to submit adversarial clinical content into a real adjudication process.
3. C-CDA handling and transformation
The final rule adopts specified HL7 guides for attachment information. A buyer should identify which guide version its product implements and where a document is validated or converted. The assessment should ask whether the content selected by the provider is the content delivered to the payer, whether an identifier changes during transformation, and whether a failed validation can leak document content into a partner-facing error or log. If a vendor stores both an original and a rendered copy, each copy needs the same tenant and claim authorization.
Include document retrieval as part of this scope. The clinically sensitive material may pass through an API, user portal, object store, support console or export. Testers should compare who can read the original, the preview, metadata and any generated download. A payer's claims staff may have a legitimate view that a clearinghouse support user should not have. The assessment report should state which roles were tested and which were outside scope.
4. Conditional electronic signature verification
First ask whether the workflow uses a transaction-time electronic signature. If it does, document who signs, what exactly is signed, how delegated rights are represented, where the verification result is recorded, and what the receiver does when verification fails. 45 CFR 162.2002(e) is conditional on a provider using an electronic signature in this transmission. The CMS FAQ summarizes the goal as signer identity, document integrity and assurance the signer cannot deny signing.
An assessment can use buyer-provided synthetic signed fixtures to verify that the implementation binds signer, document and claim as intended, recognizes the approved delegation, and does not treat a failed signature check as a successful submission. It should cover status display and exception handling as well as the verifier itself. Where the system has no signature flow, the statement of work should record that fact and exclude signature tests rather than invent a requirement to add one. Previously signed clinical source documents are not automatically subject to the transaction-time signature standard.
5. Clearinghouse segregation, retries and operations
A clearinghouse often serves multiple plans and providers through shared infrastructure. The assessment should sample tenant separation at onboarding, partner authentication, message routing, queues, support tools and operational exports. A message with a valid provider identity should not become visible to a different plan tenant because of a route mapping or support search. A valid plan request should not be delivered to a different provider simply because a reference code is reused.
Retries and manual corrections deserve explicit cases. A failed delivery may be requeued or resent; the system should preserve the original partner, claim and document context. If a support operator can override the destination, the buyer should define the authorization and audit expectations for that override. The tester can examine an approved synthetic exception and its logs. Production replay or interruption of real claims should be excluded unless the buyer has separately approved a tightly controlled plan.
6. Acknowledgments, logs and downstream access
The payer may receive an acknowledgment from the clearinghouse before an attachment is accepted into its claims record. The test should distinguish transport success from business acceptance. A sender-facing success state must not imply that the right claim received the document if an ingestion or association step later failed. The buyer can specify the reconciliation evidence it expects for each stage.
Logs should support reconstruction of a synthetic transaction without copying clinical content into a broadly accessible monitoring system. For each fixture, ask for a correlation record linking the 277 request, any 275 response, partner route, validation result, signature outcome where applicable, claim association and final disposition. Verify that authorized operations staff can find the record and that other tenants cannot. This is both a security control check and a practical way to make findings reproducible.
A quoteable test matrix
The following matrix is a procurement starting point. Replace the example identities with the buyer's actual products and authorized roles. The expected outcomes are policy assumptions to approve before testing.
Scenario | Positive case | Negative or exception case | Evidence the buyer should request |
|---|---|---|---|
277 request routing | Plan A requests a document for its claim from Provider A | Provider B or Plan B attempts to view the request | Redacted request reference, route decision, visible result and audit event |
275 attachment submission | Provider A sends the allowed document for that claim | Provider B submits against Provider A's claim | Sender authorization result, receipt status and final claim association |
Member and claim binding | One synthetic member and claim receive the intended document | Same member has two claims or two members have similar identifiers | Before and after associations at sending and payer systems |
Transformation | Accepted C-CDA content reaches the expected payer record | Document and envelope disagree on a material identifier | Validation disposition and proof of no wrong-claim filing |
Electronic signature, if used | Approved signer and document verify | Wrong signer, broken integrity or unapproved delegation | Verification state, reject or quarantine result and audit record |
Clearinghouse relay | Authorized partner route reaches the intended plan | Route or retry points to another tenant | Tenant-context decision and final destination record |
Retrieval | Claims user sees permitted attachment | Other tenant or role requests original, preview or export | Role list, denied result and redacted access logs |
The matrix should be attached to the request for proposal. It turns "test the X12 interface" into decisions a vendor can observe and report. It also prevents a bid from silently excluding the clearinghouse portal, the payer ingestion application or the document store that carries the actual exposure. A vendor can still use its own testing method, but each row should receive an in-scope, excluded or buyer-owned label.
Write the rules of engagement around claims safety
Claims attachment testing can affect clinical and financial workflows even when the entry point looks like an ordinary web app. The safest default is an environment with synthetic members, providers, plans, claims and documents. A test plan should name allowed endpoints, accounts, dates, hours, transaction volumes, stop conditions and contacts. If the team must verify a control in production, the buyer should separately approve the exact fixture and expected business effect. The ordinary engagement should avoid real adjudication, member notices, payments and clinical records.
Set a boundary for document handling. The vendor should receive only the minimum synthetic or approved redacted material needed for the cases. Reports should use transaction references and redacted screenshots rather than copying whole clinical documents. Define where logs and test artifacts are stored, who may receive them and how long the parties retain them. A business associate agreement or other contractual treatment may be relevant if the vendor will access protected health information; legal and privacy owners should decide that based on the actual data and services. A synthetic-only design can reduce the need to move sensitive data into a testing engagement.
The statement of work should also state how the tester will handle a validated issue. Findings need the affected tenant boundary, authorized and unauthorized role, observed outcome, claim or document fixture, impact, recommended fix, owner and retest condition. The report should separate vulnerabilities from configuration observations and untested assumptions. An executive summary alone is not enough for an EDI or claims engineer to reproduce a misrouted attachment safely.
What the deliverable should prove
A good report is an evidence package that can be read by security, claims operations, EDI engineering and procurement. Ask for an asset and route inventory, the approved test identities, the final policy matrix, observed positive and negative results, redacted proof for validated findings, explicit exclusions, remediation recommendations and a retest record. For each finding, show where the wrong decision happened. "Improper authorization" is less useful than a documented cross-provider view at the portal or a cross-plan association after ingestion.
Treat the payer and clearinghouse responsibilities separately. The clearinghouse may be responsible for authenticating a trading partner and preserving route context. The payer may be responsible for claim matching and retrieval permissions. A shared finding can require both teams, but the report should make that dependency visible. For a multi-vendor stack, a readout with both owners can prevent each party from assuming the other implemented the control.
Do not ask the tester to certify CMS-0053-F compliance. Conformance with the adopted transaction standards and security testing of the implementation are related but different work. A penetration test can establish observed security behavior for defined assets, roles and dates. It cannot by itself establish every regulatory requirement, every trading-partner relationship or every future exchange. Retesting can show whether a specific validated issue was fixed.
Copy-ready statement of work language
Assess the buyer's deployed electronic health care claims attachment exchange for the named payer, clearinghouse and provider-facing components. Include the X12N 277 request path, X12N 275 response path, the C-CDA attachment packaging and ingestion used by the buyer, any transaction-time electronic signature flow, and all named web, API, gateway, queue, document-store and operations interfaces in the attached asset inventory. Use buyer-supplied synthetic plan, provider, member, claim and document fixtures. Verify approved and denied decisions for request routing, sender authority, claim and member association, tenant separation, transformation, signature verification where applicable, retries, exception handling and retrieval. Deliver a redacted report with the tested roles and assets, expected policy, observed outcomes, reproducible findings, exclusions, remediation ownership and one retest of agreed fixes. Testing does not represent a CMS-0053-F certification or a regulatory attestation.
That text is a starting point, not a complete contract. Add the exact URLs, hostnames, API routes, message gateways and vendor-owned services. Name the environment and the authorized account provider. Identify whether the vendor can inspect both the sending and receiving side, because a black-box view from one end may show a receipt without proving the final claim association. Require the bidder to state which rows of the matrix it can observe directly and which will depend on buyer-provided logs.
Bid comparison should focus on scope and evidence, not just a scan count. Ask whether the vendor will test authenticated roles, whether it can inspect the 277-to-275 correlation and payer filing result, how it will handle conditional signature cases, what the retry and manual-override coverage is, and how many affected components are included. Ask who performs the work and who reviews the report. A narrower quote can be appropriate if the buyer truly owns only one component, but the exclusion should be explicit.
Plan the work before the compliance date
The final rule sets May 26, 2028 as the compliance date. It does not set a security test date. A practical program can use the remaining implementation time in stages. First, inventory the actual transaction routes and vendor contracts. Next, build synthetic fixtures and agree on the expected policy for requested, unsolicited, duplicate and exception attachments. Then test the integrated flow before broad trading-partner onboarding. Finally, retest fixes and retain a dated evidence package tied to the released version.
The sequence matters because testing an adapter before a clearinghouse route or payer ingestion exists cannot verify the full document association. Conversely, waiting until every partner is live can make safe negative tests difficult. CMS recommends working with vendors and clearinghouses and planning testing and onboarding well before the compliance date. The CMS advice is general implementation guidance; the penetration test and its timing remain the buyer's choice.
Choose retest triggers based on changes to the boundary: a new plan or provider tenant, a new clearinghouse route, a C-CDA converter, a claim matching change, a document store migration, a support override workflow or a signature service change. A prior report may still be useful as baseline evidence, but it does not prove a new implementation behaves the same way. Record version, environment, accounts and route configuration with every assessment.
Where Stingrai fits
Stingrai's web and API penetration testing is suited to the authenticated portals, APIs and application business rules in this scope. A buyer can give Stingrai synthetic plan, provider and claim roles, the approved policy matrix and a controlled environment. The output can identify observed authorization failures and give engineering a retest path. If EDI infrastructure, cloud configuration or a clearinghouse-owned system must be assessed, list those assets and permissions in the quote so the engagement reflects the actual boundary.
The fixed-price web application packages on Stingrai's pricing page cover one web application and associated APIs. A multi-party claims attachment exchange can span more than that package, so request a scope-based quote for all named systems and access levels rather than treating one application price as the cost of an end-to-end exchange. You can request a quote with the transaction map and matrix above, or book a discovery call to settle ownership and test access.
FAQ
Does CMS-0053-F require a penetration test?
No. CMS-0053-F adopts electronic claims attachment transaction and conditional electronic signature standards, with compliance required by May 26, 2028. It does not prescribe a penetration test or a testing cadence. A payer or clearinghouse can commission a test to verify its implemented security boundaries before onboarding and release.
Which transactions belong in a CMS-0053-F security scope?
The rule covers a health plan's electronic request for claim attachment information from a provider and a provider's electronic attachment transmission to a plan in support of a claim or equivalent encounter. The adopted X12N 277 request and X12N 275 response paths, related C-CDA content, and deployed gateways and retrieval paths are the core assessment inventory.
Does CMS-0053-F cover prior authorization attachments?
No. The final rule is limited to claims attachments. HHS did not finalize the proposed prior authorization attachment standards in CMS-0053-F. A payer should scope its CMS-0057-F FHIR and prior authorization API security work separately, while identifying shared components that both exchanges use.
Must every claims attachment carry an electronic signature?
No. The adopted digital signature standard applies where a provider uses an electronic signature in the claims attachment transmission. The health plan determines when a signature is needed. A buyer should test the signer, document, delegation and verification path that it actually deploys and record an exclusion when no such path exists.
What should a clearinghouse include in the test?
Include the partner onboarding and authentication path, tenant and plan routing, 277 and 275 relay, retries, exception queues, support overrides, acknowledgments and accessible logs or exports. The assessment should use distinct synthetic partners to show that one provider or plan cannot read or redirect another's request or attachment.
What evidence should the buyer ask the tester to retain?
Ask for the named assets and roles, approved policy matrix, synthetic fixture references, positive and negative results, redacted proof for each validated finding, explicit exclusions, remediation owner and retest result. The evidence should connect the request, response, document and final claim association without reproducing real clinical content.
Can one web application penetration test cover the entire exchange?
Only if that is the entire authorized boundary, which is uncommon for an exchange involving a provider, clearinghouse and payer. A proposal should name each portal, API, gateway, translator, queue, document store and owner it will cover. One application package should not be assumed to include separately operated services.
Related reading
CMS-0057-F API penetration testing scope for payers for the separate prior authorization and payer FHIR API obligations.
FHIR API penetration testing scope for shared OAuth, SMART and resource-authorization questions where a deployed FHIR interface is also in scope.
Healthcare web application penetration testing for the authenticated application and API testing method.
Sources
HHS, Administrative Simplification; Adoption of Standards for Health Care Claims Attachments Transactions and Electronic Signatures, final rule, 91 FR 14350, March 24, 2026. The operative 45 CFR 162.2001 and 162.2002 text defines the transaction, adopted standards and conditional signature provision.
CMS, CMS-0053-F final rule fact sheet, March 20, 2026. Explains the final scope and contrasts it with the proposed prior authorization attachment provisions.
CMS National Standards Group, CMS-0053-F FAQ. Clarifies covered entities, examples, signature handling and preparation advice.
CMS, CMS-0057-F final rule fact sheet. Used only to distinguish the separate payer API rule.
